{
    "nct_id": "NCT03470922",
    "official_title": "A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma",
    "inclusion_criteria": "* Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system\n* Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma\n* Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Participants must not have active brain metastases or leptomeningeal metastases\n* Participants must not have uveal melanoma\n* Participants must not have an active, known, or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}